Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Biogen Picks Up S1P Modulator To Try Competing With Novartis, Celgene

Executive Summary

Weeks after immuno-oncology tie-up with Sanofi, Evotec signs a collaboration in fibrotic disease with Pfizer. Epirus expands its biosimilars capabilities with the acquisition of Dutch biotech Bioceros.

You may also be interested in...



Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.

Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals

After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel